Resverlogix Corp. · TSX:RVX
Resverlogix — Investor Presentation (February 2021)
18 slides from Resverlogix's investor presentation, Feb 4, 2021
Slide 1: Resverlogix Corp. Corporate Breakthroughs
TSX: RVX Resverlogix Corp. Corporate Breakthroughs February 4th, 2021 – Market Update
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends",
Slide 3: Resverlogix at a Glance
Resverlogix at a Glance • Resverlogix Corp. is a Canadian public company developing an advanced cardiovascular/CKD drug called apabetalone. We are pioneering a technology that has the ability to turn multiple disease-causing genes on or off. No actual change to the human DNA Stock Symbol TSX: RVX oc
Slide 4: Financing Details
Financing Details • The pending investment transaction was announced on October 6th 2020 with an estimated closing date of January 15th, 2021. • Subsequently on October 14th 2020 ORI Capital converted its full debt position of approximately $17.5MM CDN or $13.3MM USD. • On December 3, 2020 Sheikh Ab
Slide 5: BETonMACE2 Designs and Timelines
BETonMACE2 & Designs and Timelines 5 5
Slide 6: FDA Approves Breakthrough Therapy Designation
FDA Approves Breakthrough Therapy Designation “A breakthrough therapy designation is for a drug that treats a serious or life- threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over availabl
Slide 7: Timeline Option Review - Five Year Global Development Plan
TIMELINE OPTION REVIEW - FIVE YEAR GLOBAL DEVELOPMENT PLAN Details Options Presented by and Discussed with Major Pharma’s Patient Enrollment Enrollment Interim analysys 2021 would be would would last point reached in spent enhancing commmence in until the end mid 2024 chemistry. mid 2022. of 2023. 5
Slide 8: Targeted - Global Development Plan
TARGETED - GLOBAL DEVELOPMENT PLAN Planning details between Resverlogix and various potential partners Interim analysis Pending interim success Targeted Patient of 300 targeted FDA approval is possible enrollment should enrollment will patient events due to the Breakthrough be completed 4 start H2 2
Slide 9: BETonMACE 2-Design Considerations
BETonMACE 2-Design Considerations Targeted focus on the renally impaired CV population • T2DM 7-180 days post ACS (potentially longer than 180 days – FDA opinion required) • Estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73 m2 and urinary albumin:creatinine ratio ≥200 mg/g •
Slide 10: Patient Enrichment Strategy: Annual MACE Rate
Patient Enrichment Strategy Relative Annual of Major Adverse Cardiac Events (MACE) in Target Patient Groups 30% 25.5% 25% Annual MACE Rate (%) BETonMACE BETonMACE2 Target Patients Target Patients 20% 15% 12.9% 11.4% 9.4% 10% 5% 3.0% 0.2% 0% General Population Diabetics ACS Patients with CKD Patients
Slide 11: COVID-19 Phase 2 Trial
COVID - 19 Phase 2 Trial 11 11
Slide 12: Apabetalone as A Potential Therapeutic for COVID-19
Apabetalone as A Potential Therapeutic for COVID-19 Since the initial publication demonstrating an interaction between SARS-CoV-2 proteins and BETs (Gordon et al., 2020) and our announcement in March 2020 that apabetalone reduces expression of host cell receptors, new findings from multiple labs sup
Slide 13: Number of US Deaths Due to Current Diseases in 2020
Number of US Deaths Due to Current Diseases in 2020 Posted on CNN - Nov. 2020 – AGM Slide 13
Slide 14: Number of US Deaths Due to Current Diseases in 2020 (Updated February 2021)
Number of US Deaths Due to Current Diseases in 2020 COVID-19 Updated to February 2021 460k COVID-19 deaths 14
Slide 15: Repurposing Apabetalone for SARS-CoV-2 infection with a Dual Mechanism
Repurposing Apabetalone for SARS-CoV-2 infection with a Dual Mechanism Infection of human cells with SARS-CoV-2 The SARS-CoV-2 virus causes life threatening complications including acute coronary syndrome, venous thromboembolism and hyperinflammation in the lung SARS-CoV-2 “Spike Protein” binds the
Slide 16: COVID-19 Clinical Trial Launch in Q1 2021
COVID-19 CLINICAL TRIAL LAUNCH IN Q1 - 2021 Resverlogix’ First Short Term Revenue Potential Emergency supply, Positive P2 Phase 3 will be manufacturing & FDA filing in Feb results would much faster partnership agreements 2021 & Patient launch a larger than vaccine can commence during Long term poten
Slide 17: COVID-19 Treatment Study
COVID-19 Treatment Study • This will be an open-label, exploratory clinical study to assess the patient safety and effect of oral apabetalone for up to 4 weeks compared to standard of care in hospitalized subjects with COVID-19 Infection • Hospitalized patients >18 years with NIH defined moderate il
Slide 18: Questions & Answers
TSX: RVX Questions & Answers February 4th, 2021 – Market Update